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Abstract
Purpose—Since the adoption of highly active antiretroviral therapy, HIV disease progression has 
slowed across the world; however, patients are often required to take multiple medications daily of 
poorly bioavailable drugs via the oral route, leading to gastrointestinal irritation. Recently, long 
acting antiretroviral injectables that deliver drug for months at a time have moved into late phase 
clinical trials. Unfortunately, these solid phase crystal formulations have inherent drawbacks in 
potential dose dumping and a greater likelihood for burst release of drug compared to polymeric 
formulations.
Methods—Using electrospinning, acetalated dextran scaffolds containing the protease inhibitor 
saquinavir were created. Grinding techniques were then used to process these scaffolds into 
injectables which are termed saquinavir microconfetti. Microconfetti was analyzed for in vitro and 
in vivo release kinetics.
Results—Highly saquinavir loaded acetalated dextran electrospun fibers were able to be formed 
and processed into saquinavir microconfetti while other polymers such as poly lactic-co-glycolic 
acid and polycaprolactone were unable to do so. Saquinavir microconfetti release kinetics were 
able to be tuned via drug loading and polymer degradation rates. In vivo, a single subcutaneous 
injection of saquinavir microconfetti released drug for greater than a week with large tissue 
retention.
Conclusions—Microconfetti is a uniquely tunable long acting injectable that would reduce the 
formation of adherence related HIV resistance. Our findings suggest that the injectable 
microconfetti delivery system could be used for long acting controlled release of saquinavir and 
other hydrophobic small molecule drugs.
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INTRODUCTION
According to the World Health Organization (WHO), over 35 million people worldwide are 
living with human immunodeficiency virus (HIV). Although HIV infection rates have 
slowed in recent years, the total number of people living with HIV has continued to rise(1). 
The first Food and Drug Administration (FDA) approved drug to treat HIV, azidothymidine, 
became available in 1987 and since then over 30 other drugs have been approved(2). These 
HIV drugs fall under five classes: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, 
Non-NRTIs, Protease Inhibitors (PIs), Entry/Fusion Inhibitors, and Integrase Inhibitors(2). 
Unfortunately, singular drug therapy is insufficient for effective HIV treatment, and thus, 
highly active antiretroviral therapy (HAART) consisting of multiple drug classes is required, 
every day for the rest of the patient’s life. Since the introduction of these therapies, there has 
been a dramatic reduction in mortality and morbidity allowing patients to live longer and 
healthier lives(3); however, HAART treatment can still be rendered ineffective by the 
development of drug resistance(4).
The formation of drug resistant HIV is usually a result of mutations within the HIV genome 
that occurs during a period of inadequate drug exposure, typically caused from poor 
adherence to the prescribed drug regimen(5). A recent study looking at HAART adherence 
showed that only 55% of adults in North America and 77% of adults in Sub-Saharan Africa 
reached adequate adherence rates(6). Adherence rates of 95% or higher are required for 
successful treatments with singular PI-based combination therapy, which are difficult to 
achieve(5). Due to the turnover rate of HIV within infected patients, mutations that confer 
any selective advantage, such as a reduction in susceptibility to antiretroviral therapies, will 
result in a virus that proliferates at an alarming rate(7). While undergoing HAART, the 
chances of resistance formation are significantly decreased due to the multifaceted targets of 
the therapy; however, if resistance does occur during HAART, drug therapy options become 
limited. Unfortunately, the CDC claims that around 20% of patients in the United States 
undergoing HAART do not have suppression of viral loads suggesting either drug resistance 
or lack of adherence(8).
Drug combinations such as the PI saquinavir (SQV) boosted with ritonavir (RTV)(9) have 
slightly increased patient adherence rates for effective treatment. Twice daily boosted SQV 
was shown to produce better adherence related pharmacokinetic profiles which allows for 
more “forgiveness” when adherence is not 100% as higher trough concentrations of SQV are 
maintained for longer periods of time(10). RTV works by inhibiting p-glycoprotein (Pgp) 
efflux pumps and cytochrome P450 3A4 to allow for larger bioavailability and a longer SQV 
serum half-life; however, due to SQVs hydrophobic nature, its gastrointestinal tract (GI 
tract) absorption following oral administration is still undesirable(6).
One method to increase patient compliance and thus adherence rates is to use long acting 
injectables. Long acting injectables have been used for psychiatric disorders(11), 
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contraception(12) and male hypogonadism(13) to increase compliance and allow for a 
subsequent reduction in time of inadequate drug exposure. Additionally, a subcutaneous or 
intramuscular injectable depot has the benefit of bypassing first pass metabolism, thus 
increasing drug bioavailability. This increase in drug bioavailability can drastically reduce 
the amount of drug required compared to an orally administered formulation(14). 
Furthermore, bypassing the GI tract is of importance as GI tract related adverse events are 
among the most common toxicities(15) reported with HAART that lead to regimen 
discontinuation (16, 17). Avoiding the GI tract discomfort associated with orally 
administered HAART could lead to better adherence rates from patients, which would 
reduce the chance of HIV resistant strain cultivation. Recently, TMC278 and GSK1265744 
have been investigated as long acting injectables using nanosuspensions to provide a 
month’s worth of drug in a single dose(18). While these two formulations are practical from 
an injectable mass standpoint, they do have some undesirable characteristics. One such 
characteristic is the non-tunable release kinetics because the hydrophobic interactions 
between drug and surfactant determine the rate of drug release and cannot be altered unless 
the drug or surfactant are changed(19). While long-term release is the goal, nanosuspensions 
can release drug for up to 12 months so if any site related toxicity or drug-drug interactions 
occur, the only option is to surgically remove the depot from the tissue. Additionally, depot 
drug concentrations remain extremely high even after serum drug concentrations have 
dropped below detection limits meaning there is slow and incomplete nanosuspension 
dissolution(20). Finally, nanosuspensions are not viable options for a large portion of HIV 
positive individuals who live in Sub-Saharan Africa because they are typically unstable 
outside of the cold-chain leading to uncharacterized release rates(21). This is particularly 
troubling as roughly 70% of all HIV positive individuals live within sub-Saharan Africa 
according to the WHO(1).
To help create a more manageable system without some of the side-effects observed with 
nanosuspensions, we applied a biodegradable polymer known as acetalated dextran (Ace-
DEX) that can overcome the need for cold-chain storage. We have demonstrated that protein 
encapsulation within Ace-DEX alleviated the need for cold chain storage, and maintained 
protein bioactivity at elevated temperatures(22). Ace-DEX is derived from FDA-approved 
dextran and is made hydrophobic by forming acetal groups in place of hydroxyl groups 
along the glucose rings of the parent dextran molecules. Short reaction times create a larger 
percentage of acyclic acetals, which are the kinetically favorable product of the reaction. 
Extending the reaction time increases the amount of cyclic acetals, which resist hydrolytic 
cleavage better than acyclic acetals, allowing for more sustained polymer degradation in 
aqueous environments(23, 24). By shifting the reaction time, we can effectively tune the 
degradation rate of polymer constructs from days to weeks in pH-neutral extracellular 
conditions(23). Our group has used electrospun Ace-DEX scaffolds for temporal release of 
therapeutics to be used as a topical, or surgically implantable long acting release vehicle(25). 
Since that work, our group has become interested in taking advantage of Ace-DEX’s high 
glass transition temperature (~160–190°C)(22) to process these long fibers into smaller 
injectable constructs. Polyesters such as poly lactic-co-glycolic acid (PLGA), 
polycaprolactone (PCL) and poly lactic acid (PLA) are typically used for 
electrospinning(26), however, their glass transition temperature is around 50°C and limits 
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their ability to be processed post spinning(27, 28). Here we present electrospun Ace-DEX 
scaffolds, unlike PCL and PLGA scaffolds, can be successfully processed into dispersible, 
high drug content injectables (termed Ace-DEX microconfetti (Ace-DEX-MC)) for long 
acting release. In this manuscript, we show that Ace-DEX scaffolds containing SQV at high 
loadings can be turned into MC. Saquinavir microconfetti (SQV-MC) can release drug at 
variable rates according to polymer degradability and loading, and release drug in vivo for 
more than a week from a single injection.
MATERIALS AND METHODS
A majority of the materials were purchased from Sigma Aldrich (St. Louis, MO, USA) and 
used without further modifications. Saquinavir was purchased from Proactive Molecular 
Research (Alachua, FL, USA). Water was purified using a Millipore Milli-Q integral water 
purification system (Billerica, MA, USA).
Ace-DEX synthesis from 71 and 500kDa dextran
Ace-DEX polymer was synthesized using 71 or 500kDa dextran from Leuconostoc 
mesenteroides with some modifications to the previously described protocol(23). To 
synthesize 71kDa Ace-DEX, lyophilized 71kDa dextran (1.0 g) and pyridinium p-
toluenesulfonate (0.0617 mmol) were dissolved in 10 mL of anhydrous dimethyl sulfoxide 
(DMSO). To synthesize 500kDa Ace-DEX, lyophilized 500kDa dextran (0.5 g) and 
pyridinium p-toluenesulfonate (0.0308 mmol) were dissolved in 8 mL of DMSO. Dissolved 
dextrans were reacted with Waterstone 2-ethoxypropene (Carmel, IN, USA) under nitrogen 
gas at room temperature for the desired duration to achieve 37 or 52% relative cyclic acetal 
coverage, which we will refer to as fast and slow degrading Ace-DEX, respectively. After 
the desired length of reaction, reactions were quenched with an excess of trimethylamine 
(TEA). While the acetalation process will result in increased molecular weights greater than 
71 and 500kDa, we will still refer to them as 71 and 500kDa Ace-DEX in this work. The 
reaction volumes were then precipitated in basic water (.04/99.96% v/v TEA and Water 
respectively), and centrifuged at 14,500 rpm for 10 min at 4°C using a Thermo Scientific 
sorvall legend XTR centrifuge (Waltham, MA, USA) to remove any remaining water-soluble 
polysaccharides (i.e., un-acetalated dextran and/or lowly acetalated dextran). The resulting 
pellet was then frozen and lyophilized overnight. To further purify the polymer, the product 
was dissolved in ethanol and centrifuged at 14,500 RPM for 10 min at 4°C the following 
day. The supernatant was precipitated in basic water, centrifuged again, frozen and 
lyophilized to yield 71 or 500kDa Ace-DEX polymer. The extent of cyclic acetal formation 
was determined using 1H nuclear magnetic resonance (NMR) spectroscopy based on a 
previously developed method(23).
Optimization of 71 and 500kDa Ace-DEX electrospinning
Ace-DEX scaffolds were first generated by dissolving 71 or 500kDa Ace-DEX at various 
concentrations in a hexafluoroisopropanol (HFIP), n-butanol, and TEA solution 
(59.5/39.5/1.0% v/v/v). When fully dissolved, the solution was loaded into a Hamilton 
gaslight glass model 1001 syringe (Reno, NV, USA) and a Hamilton metal hub blunt point 
needle (Reno, NV, USA) was attached. When fully primed, the syringe was loaded onto an 
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Analytical West Inc. scientific lab supply syringe pump (Lebanon, PA, USA). The syringe 
needle was connected to a positive voltage and a flat sheet of aluminum foil was connected 
to a negative voltage on a Gamma High Voltage Research power supply (Ormond Beach, 
FL, USA). When flow was initiated at 1mL/hr from the syringe pump, a voltage difference 
of roughly 15 kV was used to break the surface tension of the droplet and force the droplet 
into a Taylor cone. Following scaffold collection, small representative samples were adhered 
to Ted Pella aluminum specimen mounts (Redding, CA, USA) using carbon tape. Images 
were acquired using either an FEI NOVA NanoSEM 400 located at The Ohio State 
University, or a Hitachi S-4700 Cold Cathode Field Emission Scanning Electron Microscope 
located at the University of North Carolina.
Production of Ace-DEX, PLGA and PCL microconfetti
Scaffold production of either 71 or 500kDa Ace-DEX was performed at the optimal 
electrospinning concentration as described above. Ace-DEX scaffolds were removed from 
the aluminum foil sheet and transferred to a Kyocera CM-10 BK ceramic grinder (Costa 
Mesa, CA, USA) for processing into microconfetti (MC). Additional Ace-DEX scaffold 
samples were transferred to a Retsh 10 mL stainless steel grinder jar (Newton, PA, USA) 
that had been cooled in liquid nitrogen for 10 minutes. The loaded stainless steel grinder jar 
was then placed into a Glen Mills high speed mixer mill (Clifton, NJ, USA) and run for 5 
minutes at 10 Hz for processing into MC. Other Ace-DEX scaffold samples were sent to 
Retsch (Newton, PA, USA) to be processed into MC using a cryomill (5 minutes precool, 5 
minutes at 15 Hz). All MC samples were imaged using SEM as described above.
50:50 PLGA (50–70kDa) was dissolved in a solution of HFIP and n-butanol (80/20% v/v), 
loaded into a syringe and electrospun onto aluminum foil at 1mL/hr using a voltage 
difference of 20kV. PLGA scaffolds could not be processed using the ceramic grinder. 
Additional PLGA scaffold samples were transferred to a stainless steel grinder jar that had 
been cooled in liquid nitrogen for 10 minutes. The high speed mixer mill was run for 5 
minutes at 10 Hz. Following high speed mixer milling, the sample was removed and imaged 
using SEM.
PCL (70–90 kDa) was dissolved in pure chloroform, loaded into a syringe and electrospun 
onto aluminum foil at 3mL/hr using a voltage difference of 20kV. PCL scaffolds could not 
be processed using the ceramic grinder nor high speed mixer mill. Scaffold samples were 
sent to Retsch to be processed using a cryomill. Following cryomilling, samples were 
imaged using SEM.
Production of saquinavir loaded 71 and 500kDa Ace-DEX microconfetti
Ace-DEX scaffolds were generated by dissolving 71 or 500kDa Ace-DEX (400 or 200 
mg/mL, respectively) with the desired amount of SQV (10, 20, 30, 40 or 50% wt/wt) in a 
solution of HFIP, n-butanol and TEA (59.5/39.5/1.0% v/v/v). The SQV Ace-DEX scaffold 
was then allowed to dry under N2 gas for 5 minutes to ensure all solvents had evaporated. 
The scaffold was then processed using the ceramic grinder to yield SQV-MC and stored at 
−20°C until further use.
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Encapsulation efficiencies of SQV-MC
Following generation of Ace-DEX SQV-MC, encapsulation efficiencies were determined by 
preparing a 1mg/mL solution of SQV-MC dissolved in high performance liquid 
chromatography (HPLC) grade methanol and MilliQ water (80/20% v/v). These samples 
were analyzed using an Agilent Technologies Series 1100 HPLC (Santa Clara,CA, USA) 
with an Agilent Eclipse Plus C18 column (4.6 × 150 mm) at a flow rate of 1mL/min, 
injection volume of 60 µL and a detection wavelength of 240 nm alongside a standard curve 
of un-encapsulated SQV. The drug elution time was ~6 minutes, and following the HPLC 
run, the amount of encapsulated SQV was determined.
SQV-MC in vitro release curves
Briefly, 71 and 500kDa SQV-MC samples were suspended at a concentration of 2 mg/mL 
with 0.01% v/v Tween 80 (specific gravity = 1.06) in phosphate-buffered saline (PBS) at pH 
7.4. Once in suspension, varying quantities, dependent on SQV loadings, were placed into 
Thermo Fisher Scientific snakeskin dialysis bags with an 8kDa cutoff, (Grand Island, NY, 
USA). The dialysis bags (n = 3 per time point), were placed into 1L beakers with PBS on a 
Thermo Fisher Scientific RT2 advanced hotplate (Grand Island, NY, USA) set to 37°C. As 
the drug released from the SQV-MC, it passed through the dialysis membrane into the PBS 
sink. At each time point, individual dialysis bags were removed from the beaker and 200 mL 
of PBS sink was emptied to keep a constant dialysis bag to PBS volume ratio. Residual 
SQV-MC was removed from the dialysis bag by washing with excess basic water. This was 
then centrifuged at 4,000 RPM for 10 minutes at 4°C to pellet any residual SQV-MC. The 
supernatant was removed, and the pelleted SQV-MC was frozen and lyophilized. At the final 
time point, one additional sample was suspended in 0.01% v/v Tween 80 in PBS (pH 7.4), 
placed in a dialysis bag and then removed like every other sample. This specimen 
represented a “0 hour” time point release. Following sample lyophilization, all samples were 
dissolved in 3mL of HPLC-grade methanol and Milli-Q water (80/20% v/v) and analyzed 
using the HPLC method outlined for encapsulation efficiency. Percent SQV release was then 
calculated relative to the “0 hour” data point.
In vivo release of SQV-MC
ICR mice (female, 8–10 weeks old) were purchased from Taconic Farms (Hudson, NY, 
USA). The two groups consisted of 71kDa fast degrading 10 and 30% SQV-MC. 8 mg of 
each SQV-MC (266 mg/kg of polymer) was injected equating to roughly 26.6 and 80 mg/kg 
of SQV, respectively. SQV-MC was suspended in 0.01% v/v Tween 80 in PBS (pH 7.4), 
mice were placed under light anesthesia using isoflurane, and 300 µL was injected into the 
subcutaneous space (left flank). Collection time points were 20 minutes, 1 day, 3 days and 7 
days post injection. At each time point, mice (n = 2) were euthanized in a CO2 chamber 
followed by cardiac puncture to collect blood. Serum was then obtained by centrifuging the 
blood samples in Becton Dickinson microtainer heparin lined tubes (Franklin Lakes, NJ, 
USA) for 5 minutes in a VWR mini centrifuge (Radnor, PA, USA) and freezing it on dry ice. 
The spleen, liver, kidney and brain were also harvested and rapidly frozen in liquid nitrogen. 
All samples were then stored at −80°C until quantification.
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LC/MS Quantification of serum and tissue samples
Following extraction from the mice, serum and tissue samples were analyzed for SQV 
content based on previously published work(29). The quantity of SQV in samples was 
determined using Sciex Analyst Chromatography Software on a Sciex API-5000 triple 
quadrupole (Foster City, CA, USA) Liquid Chromatography Mass Spectrometry (LC/MS) 
machine. Calibration curves were obtained by using a weighted linear regression of 
analyte:internal standard peak area ratio vs. concentration curve. The quantity of SQV 
within each sample was determined from this calibration curve.
Results
Optimization of 71 and 500kDa Ace-DEX electrospinning
Ace-DEX scaffolds were created by electrospinning 71 and 500kDa Ace-DEX using an 
HFIP, n-butanol and TEA solution. Concentrations well below the optimal spinning 
concentration of 200 and 400 mg/mL for 71 and 500kDa, respectively, led to more erratic 
Taylor cone stability and yielded pseudo fiber-particle combinations (Figure 1 a and d). At 
concentrations closer to the optimal spinning concentration, undesirable spindly fibers with 
fewer intermittent particles were observed (Figure 1 b and e). At optimal spinning 
concentrations of 400 and 200 mg/mL for 71 and 500kDa Ace-DEX, respectively, 
homogenous ribbon-like fibers were seen (Figure 1 c and f).
Production of Ace-DEX, PLGA and PCL scaffold microconfetti
Ace-DEX scaffolds had a fluffy texture and were easily removed from aluminum foil 
whereas PLGA and PCL scaffolds were more rigid and more difficult to collect. Processed 
PLGA (high speed mix mill) and PCL (cryomill) scaffolds were completely fused (Figure 2 
a and b). The fused PLGA made collection from the jar difficult even after cooling the high 
speed mixer jar in liquid nitrogen. Cryomilled PCL formed small powdery aggregates 
without well-defined structures. Ace-DEX-MC generated by high speed mixer milling and 
cryomilling were a fine powder of small fractured fibers of relatively polydisperse size 
(Figure 2 c and d). The ribbon fiber morphology was retained throughout the grinding 
process and minimal, if any, fusion was seen. Ace-DEX-MC generated with the ceramic 
grinder was a fine powder of large fractured fibers of relatively polydisperse size (Figure 2 e 
and f). The ribbon fiber morphology was retained throughout the grinding process and 
minimal, if any, fusion was observed.
Encapsulation efficiencies of SQV-MC
Due to the large quantities of SQV required, care was taken to ensure all solids were in 
complete solution before proceeding to electrospinning. All Ace-DEX SQV-MC was loaded 
at extremely high efficiency with the lowest encapsulation efficiency being 98.2% (Table 1). 
The consistent drug loading (from initial to final) demonstrates this.
71kDa SQV-MC in vitro release curves
In vitro release profiles were generated to determine the release kinetics of SQV-MC 
depending on SQV weight loading and Ace-DEX polymer degradation rate (Figure 3 a, b, c 
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and d). All samples exhibited a burst release of SQV within the first two hours followed by 
relatively linear release afterwards. As drug loading in fast degrading Ace-DEX-MC 
increased, so too did burst release of SQV. With slower degrading Ace-DEX, however, there 
was no clear trend as burst release values remained fairly consistent across SQV loadings. 
Throughout all samples, it was seen that increasing the drug loading increased the release of 
SQV at 24 hours. In fact, with the 40% SQV-MC, there was greater than 50% SQV release 
within the first 24 hours. Throughout all samples, the slower degrading Ace-DEX showed a 
more sustained release of SQV even when increasing the SQV loading.
500kDa SQV-MC in vitro release curves
In vitro release profiles were generated from the higher molecular weight SQV-MC to 
determine if higher loading could be achieved with similar release patterns (Figure 4). Both 
the slow and fast degrading Ace-DEX exhibited a burst release of SQV within the first 2 
hours followed by relatively linear release afterwards. Similar to the 71kDa SQV-MC, an 
increase in the cyclic acetal coverage led to a reduction in the degradation rate of Ace-DEX 
and a more sustained release. Interestingly, the 50% 500kDa SQV-MC released SQV at a 
slower rate than the 40% 71kDa SQV-MC using both the fast and slow degrading Ace-DEX 
polymers.
In vivo release
Serum concentration-time profiles were generated by taking time points at 20 minutes, 1, 3 
and 7 days post injection (Figure 5). 20 minutes’ post-injection demonstrated a large burst 
release of SQV into the serum for both groups (67.45 and 144.5 ng/mL for 10 and 30% 
SQV-MC, respectively). Following the initial burst of SQV, there was a fairly linear release 
of SQV into the serum for both the 10 and 30% SQV-MC injection groups. However, on day 
7, the 10% SQV-MC injection exhibited a spike in serum concentration which boosted the 
serum concentration to 32.9 ng/mL.
Tissue SQV concentrations were analyzed from the 30% SQV-MC injection group at 20 
minutes, 1, 3 and 7 days post-injection (Figure 6). There was not any detectable SQV within 
the brain at any time point. Twenty minutes after injection, there was SQV within both the 
kidneys and liver (42.6 and 33.8 ng/mg respectively), however, SQV was undetectable 
within the spleen. SQV concentrations remained fairly stable within the liver over the 
duration of the 7 day study. One day after injection, accumulation within the kidneys and 
spleen drastically increased (315.4 and 179.3 ng/mg, respectively). Following the high 
concentration within the kidney and spleen on day 1, the concentrations dropped slightly 3 
days post injection and concentrations approached baseline levels 7 days post injection.
DISCUSSION
It has been reported that upwards of 20% of HIV positive patients within the United States 
are infected with strains that confer at least partial resistance to one or more available 
treatments with increases of more than 5% annually for at least one class of HIV 
therapies(30). The lack of adherence to HAART within the infected community could mirror 
the complications faced with treatments against other resistant pathogens (e.g., 
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Staphylococcus aureus(31) and Mycobacterium tuberculosis (MTB)(32)). Long acting drug 
delivery systems have the ability to overcome the resistance complications associated with 
non-adherence as they enable fewer administrations within the dosing regimen. Here we use 
the novel, highly loaded and tunable injectable release system of Ace-DEX-MC for the 
sustained delivery of SQV.
We were able to electrospin homogenous ribbon-like fibers of both 71 and 500kDa Ace-
DEX scaffolds by increasing the concentration of polymer within the solvent system to 400 
and 200 mg/mL, respectively, as seen in Figure 1. The ribbon morphology observed here is 
due to the highly volatile solvent system which evaporates quickly causing a polymer fiber 
shell to collapse on itself(33). During the electrospinning process, the polymer, drug and 
solvent system travel through the air to a grounded plate. As they travel, the solvent system 
evaporates leaving the polymer to harden into fibers containing the drug. Due to the fact that 
there is no external liquid continuous phase, such as the water that is commonly used in 
emulsion particle formulations(34), drug remains within the fibers which leads to the high 
encapsulation efficiencies (Table 1). Furthermore, it has been reported that when a drug is 
not readily soluble within the electrospinning solution, drug crystals are visible within the 
fibers and lead to a substantial burst release of drug even at low drug loadings(35). 
Considering SQV has relatively good solubility within our solvent system, this is not an 
issue and drug crystals are not seen on the fibers (Supplemental Figure 1).
Due to electrospun scaffolds’ ability to encapsulate drug at high loadings, they are desirable 
for extended drug delivery. Highly loaded polymeric scaffolds have been used to treat 
stenosis through surgical implantation(36); however, this is highly unfavorable and 
impractical for frequent (e.g., weekly or bi-weekly) treatments. Long acting injectables such 
as Risperdal® Consta® microparticles can have encapsulation efficiencies as low as 20%, 
which wastes a large quantity of drug(37). This can be further problematic for drugs that are 
not very potent, as these low encapsulation efficiencies lead to final weight loadings of ~12–
15% which require extremely high polymer doses for any given treatment. For example, 
SQV requires 2 g or greater for daily oral dosing (4% bioavailability without RTV), so a 
long acting injectable for weekly doses at loading similar to Risperdal® Consta® could 
require greater than 5 g of polymer, when currently the maximum amount of polymer in an 
injectable is 1.2 g for Vivitrol®(38). One of the hallmarks of the injectable nanosuspensions 
TMC278 and GSK1265744 is that the drug content is ~80% by weight and the drugs 
themselves are extremely potent allowing for minimal excipient load(18). However, the cold 
chain storage requirements significantly limit the usage of these treatments within the 
developing world, especially within sub-Saharan Africa where cold chain storage is not 
readily available(39). As previously mentioned, Ace-DEX has the ability to maintain cargo 
stability at elevated temperatures alleviating cold chain requirements that are often needed 
for other biopolymers such as PLGA(22), which further strengthens the wide applicability of 
SQV-MC. Future studies will analyze SQV-MC release kinetics and bioactivity after storage 
at elevated temperatures.
SQV is known to be more effective within T cells than within macrophages suggesting that 
SQV can be readily oxidized in oxidative environments, diminishing its activity (40). While 
the activity of SQV has not been affected by incubation with H2O2(41), SQV is highly 
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oxidized via cytochrome P450 3A4(42) and thus there exists the possibility of losing 
efficacy when stored in oxygen rich environments. Future studies will determine if 
encapsulation within MC has the ability to protect SQV from oxidation and preserve 
activity.
Because polymer scaffolds require surgical implantation and current FDA-approved long-
acting formulations have manufacturing and storage concerns, we designed a system where 
highly loaded Ace-DEX scaffolds can be processed into an injectable formulation called 
MC. As mentioned previously, Ace-DEX has a glass transition temperature of roughly 160–
190°C(22) while PLGA and PCL are closer to 50°C(27, 28). When PLGA or PCL scaffolds 
are processed using a high speed mixer mill or cryomill, respectively, the MC from these 
polymers fuse to form large aggregates (Figure 2). This occurs because a significant amount 
of local heat is generated when the ball impacts the jar(43). As the heat transfers into the 
PCL and PLGA materials, the temperature rises above their glass transition and changes 
their physical structure from rigid to amorphous which causes fusion. We have previously 
shown that microparticulate Ace-DEX can resist agglomeration at elevated temperatures 
while PLGA microparticles do not(22). Slight agglomeration of Ace-DEX fibers was 
accomplished by grinding scaffolds with a mortar and pestle as shown in Supplemental 
Figure 2; however, this technique was not used any further. Ace-DEX has the capability to 
be processed into MC of different sizes depending on the energy of the grinding procedure 
as seen within Figure 2. When we used the high speed mixer mill and cryomill (high energy 
processes), smaller MC fragments were created which could be used for intracellular 
delivery of therapeutics as these MC fragments would be readily engulfed by phagocytes, 
similarly to the elliptical disks used by Champion et al.(44). The ceramic grinder created 
larger fragments which are advantageous for sustained delivery to systemic circulation, as 
objects larger than 10 µm in length will effectively evade phagocytic uptake(45). Future 
research will be performed to determine the degree at which ceramic grinder-processed MC 
resist phagocytosis. Since our goal is to actively deliver drug into systemic circulation over 
an extended period of time, we chose to investigate the use of larger MC generated by the 
ceramic grinder.
Another advantageous characteristic of Ace-DEX is its tunable hydrolytic degradation rates 
that are simply based on the synthesis reaction time and subsequent cyclic acetal coverage. 
Polysaccharides such as dextran, used for controlled drug delivery are noted to release cargo 
via diffusion and/or dissolution(46). As seen in Figures 3 and 4, the rate of SQV release 
from SQV-MC can be increased by decreasing the cyclic acetal coverage, which 
subsequently increases the degradation rate of the polymer. Because SQV is a fairly 
hydrophobic drug with a log P value of ~ 1.9(47), it will prefer to reside within the 
hydrophobic polymer matrix rather than diffusing into the aqueous environment. Upon 
hydrolysis, the fiber will begin to erode and SQV will be released. With the faster degrading 
Ace-DEX-MC, there is a substantial burst release followed by a less drastic sustained release 
from all loadings and polymer molecular weights. We believe this large burst release occurs 
because of a combination of drug located on the surface of the fibers, and the smaller 
number of cyclic acetals (larger number of acyclic acetals) leads to more extensive initial 
hydrolysis, allowing for rapid fiber dissolution. Alternatively, the slow degrading Ace-DEX 
has a drastically smaller burst release, likely due to the fact that far more of the acetal groups 
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are cyclic acetals limiting the hydrolysis of the polymer within the first few hours in an 
aqueous solution and for the duration of release. While there is a small burst with the slower 
degrading Ace-DEX, this likely comes from the drug located on the surface of the MC. Due 
to the fact that SQV is released predominantly through polymer degradation/dissolution, 
complete drug release from implanted PLGA scaffolds could take weeks to months. In fact, 
Crow et al. have shown that drug release from PLGA fibers can have half-lives of greater 
than 9 weeks(48). The slow SQV release kinetics that PLGA would likely exhibit might lead 
to inadequate serum concentrations. Since PLGA cannot be processed into injectable MC, 
surgical implantation would be required, making PLGA very undesirable for this 
application.
There is a clear trend that with increased loading, the drug will release more quickly from 
both the fast and slow degrading Ace-DEX groups. This most likely stems from the fact that 
as the drug content within the fiber increases, the polymer matrix within the fiber becomes 
more unstable with reduced polymer entanglement that would restrict drug release. 
Interestingly, the 71kDa 40% SQV-MC releases drug faster than even the 500kDa 50% 
SQV-MC with both the fast and slow degrading Ace-DEX. We believe this occurs because at 
the weight loading of 40% with 71kDa Ace-DEX, we are approaching the solubility limit of 
SQV in our solvent system when using a concentration of ~262mg/mL. Indeed, the Taylor 
cone generated from these electrospinning conditions was less stable than the other samples, 
perhaps indicating that not all of the components were completely dissolved. When the 
molecular weight is increased to 500kDa the solution becomes more viscous, allowing for a 
smaller polymer concentration required for stable Taylor cone formation, thus leading to a 
lower SQV concentration needed for fabrication (i.e., a weight loading of 50% using 
500kDa Ace-DEX has a SQV concentration of ~200mg/mL in the solvent system).
To analyze the ability of SQV-MC to be used as a sustained delivery vehicle, we injected 
ICR mice subcutaneously with the fast degrading 71kDa 10 and 30% SQV-MC. The fast 
degrading Ace-DEX was selected because mice are known to have faster systemic 
circulation clearance rates than humans(49) and slow releasing SQV-MC might not release 
drug fast enough for sufficient serum and tissue accumulation. In fact, the total systemic 
clearance of SQV is around 4.81 L/h/kg in mice(50) and 1.14 L/h/kg in humans(51). We 
injected 8 mg of each MC formulation which contained 0.8 and 2.4 mg SQV for 10 and 30% 
SQV-MC respectively. 8mg of SQV-MC was selected because we believed it was more than 
likely that different masses of polymer would lead to differential degradation and release 
rates independent of the SQV loading. The subcutaneous administration route was selected 
considering Gautam et al. have shown that the subcutaneous space was satisfactory for 
release of antiretrovirals and enables a larger injection volume than does the intramuscular 
space(52).
For the 30% SQV-MC, a large burst was seen after injection resulting in high concentrations 
of SQV within the serum. This was not surprising as the polymer will begin degrading 
following introduction to an aqueous environment, and any surface SQV would likely be 
released instantaneously. Following the burst release from SQV-MC into the serum, the 
serum levels of SQV steadily decline as the clearance rate of SQV out of circulation was 
likely faster than the release rate of SQV from the MC. It is conceivable that high serum 
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concentrations of SQV in humans could be achieved for much longer than they were in the 
ICR mice due to the drastic differences in typical SQV clearance rates in each species. The 
10% SQV-MC saw a large burst almost instantaneously, similar to the burst seen with the 
30% SQV-MC followed by a steady decline in serum SQV concentrations. Interestingly, 
there was an unexpected secondary burst of SQV from the injection depot following 3 days 
of release. We believe this secondary burst is the result of a sudden degradation of a pocket 
of SQV-MC within the depot. The secondary burst phenomenon has previously been 
reported when using PLGA microspheres for sustained release of a hydrophobic PI which 
suggests that it could possibly be related to drug cargo(53). The concentration at which 90% 
of viral growth is inhibited (IC-90) for SQV is noted to be anywhere from 3 to 50 ng/mL in 
serum(51) which is reached during the majority of the one week timeframe with the 30% 
SQV-MC but not with the 10% SQV-MC. However, with a 4-fold lower clearance rate 
within humans, it is possible that concentrations above the IC-90 could be reached for a 
longer duration than was shown within this study. Future studies plan to use larger groups 
and use longer durations for release with SQV-MC.
When adhering to the proper HAART regimen, serum viremia can be controlled; however, 
HIV still has the ability to develop reservoir infection sites in the brain, spleen, 
gastrointestinal tract, lymphoid tissue and other organs in which there is differential drug 
distribution allowing for increased chances for resistance(54). We analyzed the tissue 
accumulation of SQV following release from the 30% SQV-MC in the same mice that had 
their serum samples analyzed. As can be observed in Figure 6, there is an initial 
accumulation peak of SQV within the tissues following one day of release from SQV-MC 
followed by a steady drop in the tissue content of SQV until 7 days when there are very low 
levels of tissue SQV. SQV is not privy to crossing the blood brain barrier as has previously 
been reported(42), most likely due to high Pgp activity at the blood brain barrier interface. It 
was our initial hypothesis that constant release of SQV into circulation could potentially 
overwhelm the available Pgp pumps allowing for some accumulation, but that action was not 
achieved. PI’s like SQV have recently been noted for inducing significant hepatotoxicity 
within HIV positive individuals(42). This may be explained by SQV predominantly being 
metabolized within the liver by cytochrome P-450 3A4(55) as well as direct passage to the 
liver after oral delivery of conventional formulations. SQV accumulation within the liver of 
our mice was lower than the drug amounts in all organs other than the brain. Thereby, our 
formulation should reduce the concentration of SQV that reaches the liver, compared to 
current oral formulations. Future work will focus on determining if constant SQV release 
from SQV-MC leads to elevated aspartate aminotransferase levels, indicative of 
hepatotoxicity as well as how these levels compare to the oral formulation.
Before the HAART era, HIV patients displayed white-pulp depletion within their 
spleens(56), which signifies significant T-cell reduction, increasing the chances for 
opportunistic infections such as bacterial pneumonia, MTB and many others(2). Since the 
induction of HAART in the mid-1990s, life expectancy, quality of life and the risk of 
opportunistic infections have dramatically improved confounded with a conservation of 
white-pulp within HIV patient’s spleens indicating the importance of the spleen within the 
HIV infection process(56). It has been reported that the spleen contains close to 15% of the 
total lymphocytes in the body (greater than any other organ) which are the primary targets of 
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HIV(57). It is therefore significant that the spleen was able to accumulate a large quantity of 
the SQV released from SQV-MC as this is a likely reservoir organ for the virus, and as a 
number of antiretroviral drugs accumulate poorly within the spleen(57).
It has been widely documented that SQV has the ability to increase the occurrence of renal 
calculi (kidney stones), however, no renal toxicity has been attributed to SQV(58). The 
largest quantity of SQV released from SQV-MC was detected within the kidneys which is 
interesting, because typically less than 1% of SQV is excreted from the kidneys (51). The 
small percentage of renal excretion probably stems from the drastic first pass metabolism 
that occurs when SQV is dosed orally, meaning that SQV-MC could radically change the 
amount of non-metabolized SQV that reaches other organs. The quantity of SQV within the 
kidneys is meaningful, because HIV can cause nephropathy due to viral replication within 
the kidney(59). In fact, HIV has been detected within podocytes, parietal cells and renal 
tubular cells at high levels highlighting the ability of HIV to cause kidney damage and the 
subsequent importance of drug delivery to the kidney(60).
One aspect which was not investigated within this work is to boost SQV with RTV as is 
performed within the clinic(61, 62) which can lead to an increase in the orally administered 
area under the curve and Cmax of SQV by over 50 and 22 fold, respectively(63). The 
potential to increase the serum concentrations and allow for passage through the blood brain 
barrier and testes using RTV could be coupled with the slow degrading SQV-MC, allowing 
for sustained delivery over a longer period of time than was achieved in the current study. A 
longer sustained release period from Ace-DEX-MC would lead to fewer required 
administrations and would cut down on the potential for non-adherence related 
complications. Additionally, if the serum concentrations are increased for a longer duration, 
it is likely that there will be a larger accumulation of SQV within the tissues(64) allowing 
for enhanced anti-viral activity throughout many of HIV’s tissue reservoirs.
CONCLUSION
We have presented a novel, highly loaded delivery vehicle for the long acting release of 
saquinavir into systemic circulation to counteract adherence related resistance in the 
treatment of HIV. We show stable and relatively uniform fiber generation along with high 
encapsulation efficiencies of drug. Most interesting, is the ability to process our scaffolds 
into injectable MC and fine tune the release kinetics by changing the Ace-DEX carrier 
polymer’s hydrolytic stability (cyclic acetal coverage) and total drug loading. These flexible 
options are unique to Ace-DEX and not possible with more ubiquitously used biodegradable 
polymers like PLGA. Finally, our work suggests that Ace-DEX-MC presents a platform by 
which other hydrophobic small molecule drugs can be loaded and released over time for 
enhanced pharmacologic effect.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Scanning electron micrographs with scale bar indicating 5 µm for electrospun constructs 
fabricated from 71kDa acetalated dextran (Ace-DEX) at a concentration of a) 200 mg/mL, 
b) 300 mg/mL and (c) 400 mg/mL, and 500kDa Ace-DEX at a concentration of d) 100 
mg/mL, e) 150 mg/mL and f) 200 mg/mL.
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Figure 2. 
Scanning electron micrographs with scale bar indicating 10 µm of a) poly lactic glycolic 
acid (PLGA), b) polycaprolactone (PCL), c–e) 71kDa acetalated dextran (Ace-DEX) and f) 
500kDa Ace-DEX scaffolds processed by a,c) high speed mixer milling, b,d) cryomilling or 
e, f) ceramic grinding.
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Figure 3. 
In vitro saquinavir release profiles performed at pH 7.4 for drug loaded microconfetti 
composed of fast or slow degrading (37 and 52% cyclic acetal coverage, respectively) 71kDa 
acetalated dextran with different drug weight loadings: a) 10%, b) 20%, c) 30% and d) 40%. 
Data are presented as mean ± standard deviation (n=3).
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Figure 4. 
In vitro saquinavir release profiles performed at pH 7.4 for microconfetti with a drug weight 
loading of 50%, composed of fast or slow degrading (37 and 52% cyclic acetal coverage, 
respectively) 500 kDa acetalated dextran. Data are presented as mean ± standard deviation 
(n=3).
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Figure 5. 
Serum concentrations of saquinavir (SQV) following in vivo release from fast degrading 
(37% cyclic acetal coverage) 71kDa acetalated dextran microconfetti loaded with 10 and 
30% SQV by weight. Data are presented as mean ± standard deviation (n=2).
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Figure 6. 
Tissue concentrations of saquinavir (SQV) following in vivo release from fast degrading 
(37% cyclic acetal coverage) 71kDa acetalated dextran microconfetti loaded with 30% SQV 
by weight. Data are presented as mean ± standard deviation (n=2).
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